{"type":"trials","record":{"id":42069,"source_id":"clinicaltrials-gov","external_id":"NCT02305238","title":"Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration","brief_summary":"To assess the efficacy of intravitreal (IVT) administration of aflibercept with two different approaches of Treat and Extend dosing regimens in Japanese subjects with neovascular (wet) Age-related Macular Degeneration (wAMD) . To assess the safety of IVT administration of aflibercept with two different approaches of Treat and Extend dosing regimen in Japanese subjects with wAMD for up to 2 years.","overall_status":"Completed","phases":["PHASE4"],"study_type":"INTERVENTIONAL","sponsor":"Bayer","enrollment":288,"countries":["Japan"],"start_date":"2014-12-19","completion_date":"2017-12-20","last_update_date":"2023-11-18","source_url":"https://clinicaltrials.gov/study/NCT02305238","editorial_summary":"A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"ALTAIR","age_range":"50 Years","comparator":null,"organization":"Bayer","interventions":["Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Mean Change From Baseline in BCVA at Week 52 — Baseline and Week 52","Percentage of Participants Who Maintained Vision at Week 52 — Week 52","Percentage of Participants Who Gained at Least 15 Letters of Vision Compared to Baseline at Week 52 — Baseline and Week…","Mean Change in Central Retinal Thickness (CRT) From Baseline at Week 52 — Baseline and week 52","Percentage of Participants Without Fluid on Optical Coherence Tomography (OCT) at Week 52 — Week 52"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":true},"controlled_terms":["Wet Macular Degeneration","Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct02305238","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2014-12-19 to 2017-12-20","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.915Z","intervention":["Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)"],"participants":288,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE4","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Mean Change From Baseline in BCVA at Week 52 — Baseline and Week 52","Percentage of Participants Who Maintained Vision at Week 52 — Week 52","Percentage of Participants Who Gained at Least 15 Letters of Vision Compared to Baseline at Week 52 — Baseline and Week…","Mean Change in Central Retinal Thickness (CRT) From Baseline at Week 52 — Baseline and week 52","Percentage of Participants Without Fluid on Optical Coherence Tomography (OCT) at Week 52 — Week 52"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42069","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}